Literature DB >> 30898965

Salmonella enterica serovar enteritidis peritonitis with spontaneous intestinal perforation in an immunocompetent patient.

Marion Hélias1, Jérôme Planchon1, Aurore Bousquet1, Clément Dubost1.   

Abstract

Few data reported non-typhoidal Salmonella peritonitis in immunocompromised patients. We reported the case of a man without immunosuppression or predisposing factor, who developed Salmonella enterica serovar Enteritidis peritonitis with spontaneous intestinal perforation. After emergent surgery, the patient was transferred to intensive care unit (ICU) because of respiratory, renal and haemodynamic failures. When S. enterica serovar Enteritidis was identified, antibiotics were de-escalated for ceftriaxone and metronidazole for 5 days. No immunosuppression was found. Evolution was favourable, and the patient has been discharged from the ICU on day 8. The originality of this case arises from a perforation peritonitis secondary to S. enterica without any immunosuppression. In absence of non-Typhi Salmonella data, we treated this patient as a typhoid perforation: surgical treatment, antibiotic association and supportive care. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adult intensive care; hepatitis and other GI infections

Mesh:

Substances:

Year:  2019        PMID: 30898965      PMCID: PMC6453334          DOI: 10.1136/bcr-2018-228027

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  16 in total

Review 1.  Progress in management of typhoid perforation.

Authors:  A Y Ukwenya; A Ahmed; E S Garba
Journal:  Ann Afr Med       Date:  2011 Oct-Dec

Review 2.  [Toxic megacolon and intestinal perforation caused by Salmonella enteritidis].

Authors:  A Castells; M Q Cardona; E Pedrol; M Navarro; J Casademont; A Coca
Journal:  Rev Clin Esp       Date:  1990-04       Impact factor: 1.556

Review 3.  Non-typhoidal Salmonella in children: microbiology, epidemiology and treatment.

Authors:  Gabrielle M Haeusler; Nigel Curtis
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  Non-Typhi, non-Paratyphi Salmonella-related hospitalisations in Spain: trends, clinical aspects, risk factors for worse prognosis and hospital costs.

Authors:  Macarena Garrido-Estepa; P Latasa; G Y Ordóñez-León; M Martínez-Avilés; A de la Torre; L García-Comas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-20       Impact factor: 3.267

5.  Perforation of toxic megacolon in non-typhoid Salmonella enterocolitis spares young infants and is immune-mediated.

Authors:  C-H Chiu; L-H Su; C-C He; T-H Jaing; C-C Luo; T-Y Lin
Journal:  Pediatr Surg Int       Date:  2002-04-25       Impact factor: 1.827

6.  Typhoid perforation of the bowel. Experiences in 78 cases.

Authors:  F C Eggleston; B Santoshi; C M Singh
Journal:  Ann Surg       Date:  1979-07       Impact factor: 12.969

Review 7.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

8.  A large outbreak of typhoid fever associated with a high rate of intestinal perforation in Kasese District, Uganda, 2008-2009.

Authors:  Karen P Neil; Samir V Sodha; Luswa Lukwago; Shikanga O-Tipo; Matthew Mikoleit; Sherricka D Simington; Peter Mukobi; Stephen Balinandi; Samuel Majalija; Joseph Ayers; Atek Kagirita; Edward Wefula; Frank Asiimwe; Vianney Kweyamba; Deborah Talkington; Wun-Ju Shieh; Patricia Adem; Brigid C Batten; Sherif R Zaki; Eric Mintz
Journal:  Clin Infect Dis       Date:  2012-02-22       Impact factor: 9.079

9.  [Intestinal perforation caused by Salmonella typhimurium].

Authors:  Timme M A J van Vuuren; Johannes A Wegdam; Marjolijn C A Wegdam-Blans
Journal:  Ned Tijdschr Geneeskd       Date:  2013

10.  In contrast to morphine, buprenorphine enhances macrophage-induced humoral immunity and, as oxycodone, slightly suppresses the effector phase of cell-mediated immune response in mice.

Authors:  Iwona Filipczak-Bryniarska; Katarzyna Nazimek; Bernadeta Nowak; Michael Kozlowski; Magdalena Wąsik; Krzysztof Bryniarski
Journal:  Int Immunopharmacol       Date:  2017-12-01       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.